|
|
The 3rd World Congress on
Controversies in Urology (CURy)
Hilton Hotel, Athens, Greece, February 25-28, 2010 |
|
| |
| Scientific Program |
 |
|
|
|
Friday, February 26, 2010 |
|
|
PROGRESS IN MINIMALLY-INVASIVE SURGERY (MIS):
IS LAPARO-ENDOSCOPIC-SINGLE-SITE SURGERY (LESS) HERE TO STAY?
An unrestricted educational grant by Olympus Medical Systems Europa (GMBH) |
|
08:30-10:00 |
|
|
Chairpersons:
|
J.-U. Stolzenburg, Germany & E. Liatsikos, Greece
|
|
|
Welcome and Introduction
J.-U. Stolzenburg, Germany
|
|
LESS: Instrumentation and evaluations
E. Liatsikos, Greece
LESS: Radical prostatectomy
F. Gaboardi, Italy
LESS: Transvaginal access
A. Alcaraz, Spain
LESS and its future: Tumor nephrectomies
J.-U. Stolzenburg, Germany
LESS: In gynecology
F. Fanfani, Italy
LESS: In general surgery
H. Weiss, Austria
|
|
|
Summary and Discussion
J.-U. Stolzenburg, Germany
|
| |
|
| Session 2 |
PROSTATE CANCER: PSA FAILURE AFTER TENTATIVE CURATIVE TREATMENT |
|
08:30-10:00 |
|
| Capsule: |
Are there new strategies in the approach to failure of curative therapy? |
| Chairpersons: |
L. Klotz, Canada & V. Rombis, Greece
|
| 08:30-08:35 |
Welcome
V. Rombis, Greece
|
| 08:35-08:45 |
What is the correct PSA threshold to define failure after surgery and irradiation?
J. Moul, USA |
| |
|
|
08:45-08:55
|
Evaluation of rising PSA
Role of biopsy: L. Boccon-Gibod, France |
| |
|
|
08:55-09:30
08:55-09:05
09:05-09:20
09:20-09:30 |
Rising PSA after radical prostatectomy
Management with X-ray therapy (XRT): When, to whom, how much?
R. Burette, Belgium
Hormonal therapy: When to initiate?
Speaker: Z. Dotan, Israel
Discussant: J. Anderson, UK
Is there a place for surveillance?
L. Klotz, Canada |
| |
|
|
09:30-10:00
09:30-09:40
09:40-09:50
09:50-10:00
|
Rising PSA after brachytherapy / radiation
Management with surgery: When, to whom?
Speaker: J. Anderson, UK
Discussant: J. Moul, USA
Management with hormonal therapy: Early vs. delayed
Speaker: F. Debruyne, UK
Discussant: S. Egawa, Japan
Role of minimally invasive salvage therapies, i.e. Cryo, HIFU, photodynamic therapy
Z. Symon, Israel
|
|
|
| 10:00-10:30 |
Coffee Break |
| |
|
|
|
MEASURING OUTCOMES IN OVER-ACTIVE BLADDER (OAB): PAST, PRESENT AND FUTURE
An unrestricted educational grant by Astellas Pharma Europe Ltd. |
|
10:30-12:00 |
|
|
Chairperson: |
D. de Ridder, Belgium |
|
|
|
|
10:30-11:00
|
Debate: Urodynamics remain the gold standard for assessment and measurement
Pro: A. Apostolidis, Greece
Con: P. Radziszewski, Poland |
|
|
|
|
11:00-11:30
|
Debate: Patient reported outcomes are the most important and relevant way of measuring success
Pro: E. Costantini, Italy
Con: M. Speakman, UK |
|
|
|
|
11:30-12:00
|
Debate: The use of biomarkers will become standard in the management of OAB in the future
Pro: C. Fowler, UK
Con: F. Cruz, Portugal
|
|
|
|
|
|
BLADDER CANCER: NON-MUSCLE INVASION
An unrestricted educational grant by Kyowa Hakko Kirin |
| 10:30-12:00 |
|
| Capsule: |
Recurrence under treatment: What are the different options? |
| Chairpersons: |
J. Palou, Spain & A. Skolarikos, Greece |
|
|
|
|
10:30-10:40
10:40-12:00
|
Opening remarks
Panel discussion & Case study for:
Immediate treatment: When? For which patients?
Recurrence under treatment: What are the different options?
Prognostic factors
Panel:
M. Brausi, Italy
F. Witjes, The Netherlands
W. Oosterlinck, Belgium
|
| |
|
|
|
DISCUSSION ON KEY CONTROVERSIES IN THE MANAGEMENT OF PROSTATE CANCER
Satellite Symposium by Astellas Pharma Europe Ltd. |
| 12:00-13:30 |
|
| Chairperson: |
L. Boccon-Gibod |
| |
|
|
Introduction
Chairperson
Multidisciplinary care in prostate cancer: What is the added value?
B. Tombal, Belgium
Testosterone monitoring in prostate cancer: Is it important?
C. Schulman, Belgium
Early management of prostate cancer: When and how?
J. Irani, France
Treatment of advanced prostate cancer: Can we reduce the impact on the patient's quality of life?
T. Oliver, UK
Discussion and take home messages
Chairperson, Faculty and Participants
|
| |
|
| 13:30-14:30 |
Lunch Break |
| |
|
|
|
CONTROVERSIES IN THE MANAGEMENT OF MALE LUTS: go with the flow or go for the patient
An unrestricted educational grant by Astellas Pharma Europe Ltd. |
| 14:30-16:00 |
|
|
Chairperson: |
F. Debruyne, The Netherlands |
| |
|
|
14:30-15:00
|
It is about LUTS: controversies in the aetiology and diagnosis of LUTS in male patients
Patient case discussion: Chairperson & Audience
Evidence lecture: K. Stravodimos, Greece |
| |
|
| 15:00-15:30 |
Disrupted sleep in male LUTS patients: the neglected consequence of nocturia?
Patient case discussion: Chairperson & Audience
Evidence lecture: N. Stanley, UK |
| |
|
| 15:30-16:00 |
Male LUTS: is individualizing treatment against the flow?
Patient case discussion: Chairperson & Audience
Evidence lecture: P. van Kerrebroeck, The Netherlands |
| |
|
| Session 7 |
TESTICULAR CANCER MANAGEMENT |
| 14:30-16:00 |
|
| Capsule: |
Is there agreement on the treatment of stage-I testicular cancer? |
| Chairpersons: |
N. Fleshner, Canada & F. Sofras, Greece |
| |
|
| 14:30-14:50 |
Debate: Testicular-sparing surgery
For: N. Fleshner, Canada
Against: V. Matveev, Russia |
|
|
| 14:50-15:15 |
Debate: Therapeutic options for stage-I seminoma
Surveillance: A. Bamias, Greece
Irradiation: H. Payne, UK
Chemotherapy: J. Bellmunt, Spain |
|
|
| 15:15-15:40 |
Debate: Treatment options for stage-I non-seminomatous tumors
Surveillance: Z. Dotan, Israel
Surgery: J. Pinthus, Canada
Chemotherapy: J. Bellmunt, Spain |
| |
|
| 15:40-16:00 |
Retroperitoneal lymph node dissection (RPLND): Panel discussion
Post-chemotherapy only?
Experience with laparoscopic RPLND
Moderator: N. Fleshner, Canada
Panel:
A. Alcaraz, Spain
A. Bamias, Greece
V. Matveev, Russia
U. Studer, Switzerland
H. Payne, UK
|
| |
|
| 16:00-16:30 |
Coffee Break |
|
|
| Session 8 |
PROSTATE CANCER PREVENTION, SCREENING AND EARLY DIAGNOSIS |
| 16:30-17:30 |
|
| Capsule: |
Do we need to change the approach to prostate cancer screening and prevention? |
| Chairpersons: |
S. Egawa, Japan & Y. Fradet, Canada |
| |
|
|
16:30-16:40
16:40-16:50
16:50-17:00
17:00-17:10
|
Prevention rationale: What have we learned from the PCPT and REDUCE trails?
N. Fleshner, Canada
What are other possible prevention options?
S. Horie, Japan
Who should be screened? A critical assessment of the PLCO and ERSPC studies
P. Rischmann, France
The potential role of diagnostic markers
Y. Fradet, Canda
|
|
17:10-17:30
|
Discussion
|
| |
|
|
|
RENAL TUMORS: CASE DISCUSSION DEBATES |
|
16:30-17:30 |
|
| Capsule: |
Is there are standard treatment for all renal tumors? |
| Chairperson: |
M. Marberger, Austria & C. Constandinidis, Greece |
| |
|
| 16:30-17:30 |
Panel:
A. Bamias, Greece
J. Fitzpatrick, UK
V. Matveev, Russia
M. Soloway, USA
C. Sternberg, Italy
J.-U. Stolzenburg, Germany |
|
Saturday, February 27, 2010 |
|
|
NON-MUSCLE INVASIVE BLADDER CANCER
Transurethral resection (TUR) quality control, How to improve outcomes,
Controversies in the management of T-1 disease
An unrestricted educational grant by General Electric (GE) |
| 08:30-10:00 |
|
| Capsule: |
Can we reduce recurrence and progression of non-muscle invasive bladder cancer by improving TUR? |
| Chairpersons: |
M. Soloway, USA & J. Varkarakis, Greece |
| |
|
|
08:30-08:45
08:45-09:00
09:00-09:15
09:15-10:00 |
Quality control of transurethral resection of the bladder (TURB)
M. Soloway, USA
Can we improve TURB?
P. Geavlete, Romania
Improving outcomes and the role of Hexvix in reducing recurrence
D. Zaak, Germany
Controversies in T1 disease
When Re-transurethral resection of bladder tumor (TURBT) is indicated?
When a radical cystectomy should be considered?
Can we improve intravesical therapy?
H. Botto, France
M. Soloway, USA
F. Witjes, The Netherlands
|
|
|
|
|
|
MEN'S HEALTH: Erectile dysfunction (ED) and testosterone deficiency (TD) |
| 08:30-10:00 |
|
| Capsule: |
Current approaches to ED and TD: What new have we learned? |
| Chairpersons: |
D. Hatzichristou, Greece & E. Wespes, Belgium |
| |
|
|
08:30-08:45
08:45-09:00
|
Erectile dysfunction: Tip of the iceberg of cardio-vascular diseases
Sponsored by Itamar Medical
ED = Endothelial dysfunction?
E. Wespes, Belgium
Which ED patients are at cardiovascular risk?
R. Virag, France |
| |
|
|
09:00-09:10
09:10-09:20
09:20-09:30 |
Can we cure ED?
Daily dose vs. On demand PDE5-I after prostatectomy
A. Salonia, Italy
Shock wave treatment: A novel approach with a potential for cure
Y. Vardi, Israel
Implantation of penile prosthesis: A disappearing procedure?
D. Hatzichristou, Greece |
| |
|
|
09:30-09:45
09:45-10:00
|
Testosterone deficiency
Sponsored by Ferring Pharmaceuticals
Risks and benefits of testosterone treatment
M. Zitzmann, Germany
Which treatment for ED patients with TD?
C. Schulman, Belgium
|
| |
|
| 10:00-10:30 |
Coffee Break and Poster Viewing |
| |
|
|
|
STRATEGIES FOR OPTIMIZING OUTCOMES IN GENITOURINARY (GU) MALIGNANCIES
Supported by Novartis Oncology |
| 10:30-12:00 |
|
| Capsule: |
Are there new strategies in the approach of bone metastasis in GU malignancies? |
| Chairpersons: |
G. Moutzouris, Greece & F. Saad, Canada |
| |
|
|
Introduction: Importance of bone health in GU cancers: G. Moutzouris, Greece
Optimal outcomes in metastatic renal cell carcinoma (RCC) and bladder cancer: C. Schulman, Belgium
Optimal outcomes in metastatic prostate cancer: M. Colombel, France
Anticancer effects of zoledronic acid (ZOL): F. Saad, Canada |
| |
|
| |
Questions & Answers:
Factors that contribute to optimal outcomes in advanced GU malignancies (value of bone health)
-Pain reduction
-Increased QoL
-Cost effectiveness
-Effective even in late-stage disease
Potential anti-cancer properties of bisphosphonates (BPs) in GU malignancies
-ZOL anticancer mechanism of action: Data in prostate, kidney and bladder cancers
|
|
|
|
|
|
MINIMAL AND LOCALIZED PROSTATE CANCER |
|
10:30-12:00 |
|
| Capsule: |
Has active surveillance become a treatment option for selected patients? |
|
Chairpersons: |
J. Irani, France & A. Deliveliotis, Greece |
| |
|
|
10:30-11:00
|
Debate: Selecting patients for active surveillance: Should present criteria be enlarged or reduced?
Enlarged: L. Klotz, Canada
Reduced: J. Moul, USA |
| |
|
|
11:00-11:40
|
Debate: Triggers for therapy in patients on active surveillance
Prostate specific antigen (PSA) kinetics and diagnostic markers
Can magnetic resonance imaging and spectroscopy prove useful?
Can 5-Alpha-Reductase influence patients' selection?
Panel:
Y. Fradet, Canada
N. Fleshner, Canada
W. Oosterlinck, Belgium
M. Soloway, USA |
| |
|
|
11:40-12:00
|
Debate: Radiation + hormone: Is the survival benefit balanced by the side effects?
Combination therapy: H. Payne, UK
Radiation alone: Z. Symon, Israel
|
| |
|
|
|
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR BLOCKADE: THE NEW APPROACH TO PROSTATE CANCER MANAGEMENT
An unrestricted educational grant by Ferring Pharmaceuticals |
|
12:00-13:30 |
|
| Capsule: |
What is new in hormonal therapy for prostate cancer? |
|
Chairpersons:
|
J. Anderson, UK & I. Vakalopoulos, Greece
|
|
12:00-12:05
|
Welcome and Objectives
|
|
12:05-12:25
12:25-12:45
12:45-13:05
13:05-13:25
|
Clinical development of a new GnRH blocker:
B.-E. Persson, Switzerland
Firmagon vs. Leuprolide: What is the difference?
B. Tombal, Belgium
Which patients will benefit from GnRH blocker therapy?
J. Anderson, UK
Neoadjuvant/adjuvant hormonal treatment
H. Payne, UK
|
|
13:25-13:30
|
Conclusions
J. Anderson, UK
|
|
|
|
|
|
MALE URINARY INCONTINENCE |
|
12:00-13:30 |
|
| Capsule: |
Can we agree on a solution to all male urinary incontience? |
| Chairpersons: |
F. Cruz, Portugal & N. Sofikitis, Greece |
|
|
|
|
12:00-12:10
12:10-12:20
|
How big is the problem and how should it be handled?
L. Boccon-Gibod, France
Incontinence after radiation therapy (RT) for prostate cancer?
D. de Ridder, Belgium |
| |
|
|
12:20-13:00
|
Surgical options: Pros and Cons
AUS: J. Heesakkers, The Netherlands
Invance: P. Dinis, Portugal
Obturator tapes: D. Waltregny, Belgium
ProAct balloons: P. Radziszewski, Poland |
| |
|
|
13:00-13:30
|
Clinical cases
Moderator: F. Cruz, Portugal
Panel:
L. Boccon-Gibod, France
D. de Ridder, Belgium
P. Dinis, Portugal
J. Heesakkers, The Netherlands
P. Radziszewski, Poland
D. Waltregny, Belgium
|
|
|
|
|
13:30-13:40
|
Best Abstract Award Ceremony
Sponsored by Pfizer Oncology |
| 13:40-14:30 |
Lunch Break |
| |
|
|
|
KEY CONTROVERSIES IN ADVANCED GENITOURINARY (GU) CANCERS
An unrestricted edcuational grant by Sanofi Aventis |
|
14:30-16:00 |
|
| Capsule: |
Can we improve outcomes for patients with advanced GU cancers? |
| Chairpersons: |
J. Fitzpatrick, UK & C. Sternberg, Italy |
|
|
|
|
14:30-14:35
|
Opening and Welcome
C. Sternberg, Italy |
|
|
|
|
14:35-14:50
14:50-15:15
15:15-15:35
15:35-15:55
|
Controversies concerning European and US screening studies
J. Fitzpatrick, UK
Management of advanced prostate cancer: Challenges and controversies - Asymptomatic patients and senior adults
A. Zlotta, Canada
Beyond docetaxel: When and whom to consider?
S. Oudard, France
Exploring the unmet needs in metastatic castrate-resistant prostate cancer (mHPRC): What does the future hold?
C. Sternberg, Italy |
| |
|
|
15:55-16:00
|
Summary
J. Fitzpatrick, UK
|
| |
|
|
|
ENDOUROLOGY & NEPHROLITHIASIS
An unrestricted educational grant by Karl Storz |
| 14:30-16:00 |
|
| Capsule: |
Is there a best approach to treat a kidney stone? |
| Chairperson: |
P. Geavlete, Romania & D. Mitropoulos, Greece |
| |
|
|
14:30-15:00
|
Debate: Supine vs. Prone position during percutaneous nephrolithotomy (PCNL)
Supine position: R. Scarpa, Italy
Prone position: P. Conort, France |
| |
|
|
15:00-16:00
|
Debate: Difficult situation: Is there a limit?
Moderator: M. Marberger, Austria
Panel:
P. Conort, France
R. Scarpa, Italy
A. Skolarikos, Greece
H. Winkler, Israel
|
|
|
|
| 16:00-16:30 |
Coffee Break and Poster Viewing |
| |
|
|
|
BENIGN PROSTATIC HYPERPLASIA (BPH) SURGICAL MANAGEMENT
An unrestricted educational grant in part by American Medical Systems |
|
16:30-18:00 |
|
| Capsule: |
Green light (GL) laser session on the treatment of outflow obstruction |
| Chairpersons: |
G. Alivizatos, Greece & F. d'Ancona, The Netherlands |
| |
|
|
16:30-16:40
16:40-16:50
16:50-17:00
17:00-17:10
17:10-17:20
17:20-17:30
17:30-17:40
17:40-17:50
|
Why do we need an alternative to the gold standard and TURP in the first place?
G. Alivizatos, Greece
What evidence is provided by published papers that the GL laser is effective?
A. Bachmann, Switzerland
Can we treat big prostates and big middle lobes with the GL laser?
F. Gomez-Sancha, Spain
Tips, tricks and pearls for successful GL patient outcomes
F. d'Ancona, The Netherlands
No tissue, no biopsy with the GL laser: Is that a problem?
F. Schiefelbein, Germany
Patients under anticoagulation therapy and patients in retention: Can they be treated?
N. Barber, UK
Is the GL laser a better surgical treatment alternative to that of traditional TURP? What are the major differences in relation to other lasers?
F. Gomez-Sancha, Spain
Is it possible that in the future lasers may compete with medical treatment?
G. Alivizatos, Greece |
| |
|
|
17:50-18:00
|
Questions and answers
|
| |
|
|
|
LOCALLY ADVANCED BLADDER CANCER: CASE DISCUSSION |
|
16:30-18:00 |
|
| Capsule: |
Can we adapt a solution to all patients will locally advanced disease? |
| Chairpersons: |
A. Zlotta, Canada & A. Antoniou, Greece |
| |
|
| 16:30-16:45 |
Neoadjuvant or adjuvant chemotherapy when the renal function is impaired: for some patients, for all patients, for no patients?
A. Bamias, Greece |
| |
|
| 16:45-17:00 |
Locally-advanced bladder cancer: When the margins are positive
M. Soloway, USA |
| |
|
| 17:00-18:00 |
Case discussion
Does surgery offer some hope of cure when the nodes are grossly positive?
Contraindications to neo-bladder reconstruction
Management of advanced bladder cancer with hydronephrosis and kidney failure
Moderator: A. Zlotta, Canada
Panel:
A. Bamias, Greece
Y. Fradet, Canada
W. Mansson, Sweden
M. Soloway, USA
U. Studer, Switzerland
|
|
Sunday, February 28, 2010 |
| Session 20 |
URINARY DIVERSION |
| 09:00-10:30 |
|
| Capsule: |
Is there a best urinary diversion? Can we improve selection? |
| Chairpersons: |
R. Hautmann, Germany & S. Horie, Japan |
| |
|
| 09:00-10:00 |
Urinary diversion following cystectomy for bladder cancer: Advantages and disadvantages
Conduits: M. Marberger, Austria
Orthotopic diversion in males: U. Studer, Switzerland
Orthotopic diversion in females: A. Stenzl, Germany
Continent cutaneous diversion: W. Mansson, Sweden
Anal sphincter diversion: H. Botto, France |
| |
|
| 10:00-10:25 |
Case discussion
Moderator: R. Hautmann, Germany
Panel:
H. Botto, France
W. Mansson, Sweden
M. Marberger, Austria
A. Stenzl, Germany
U. Studer, Switzerland |
| |
|
| 10:25-10:30 |
Conclusion
R. Hautmann, Germany
|
|
|
| 10:30-11:00 |
Coffee Break and Poster Viewing |
|
|
|
|
LOOKING AT OUTCOMES
Surgery for bladder and prostate cancer
Open vs. Lap vs. Robotic |
| 11:00-12:30 |
|
| Capsule: |
Open vs. Lap vs. Robotic: Is there a winner? |
| Chairpersons: |
A. Alcaraz, Spain, U. Studer, Switzerland & J. Ramon, Israel |
| |
|
|
11:00-11:50
11:00-11:15
11:15-11:30
11:30-11:45 |
Surgery for bladder cancer
Operative time and hospital stay
Operative complications
Lymph node dissection
Surgical margins
Cutaneous or orthotopic diversion
Progression free survival
Cancer-specific survival
Overall survival
Urinary continence
Potency preservation
Open: R. Hautmann, Germany; A. Zlotta, Canada
Lap: T. Piechaud, France
Robotic: J. Palou, Spain
|
| 11:50-12:00 |
Outcomes summary for bladder cancer: Open vs. Lap vs. Robotic:
A. Stenzl, Austria
|
|
12:00-12:50
12:00-12:15
12:15-12:30
12:30-12:45
|
Surgery for prostate cancer
Operative time and hospital stay
Operative complications
Lymph node dissection
Surgical margins
Progression free survival
Cancer-specific survival
Overall survival
Urinary continence
Potency preservation
Open: C. Barre, France; M. Soloway, USA
Lap: S. Egawa, Japan
Robotic: T. Piechaud, France
|
| 12:50-13:00 |
Outcomes summary for prostate cancer: Open vs. Lap vs. Robotic:
A. Alcaraz, Spain |
| |
|
| 13:00-13:30 |
Drinks & Sandwiches |
|
|
|
|
WebStudio.co.il